Welcome to the future of HCS: Fluofarma in 3D

3D High Content Screening

3D cell cultures are expected to have an enormous impact on cell biology over the coming years. Fluofarma now implements and masters a new 3D HCS technology using microtissues in a 96-well plate format. This methodology is scaffold-free, so the same standardized HCS approaches can be used as with classic 2D cultures.

Enhancing the information content

The striking similarity of the morphologies and behaviors of cells grown in 3D culture and those of the same cell type in vivo is now widely accepted. As such, 3D cell cultures are becoming essential for increasing the relevance of assays to the in vivo situation and its predictive validity.
HCS in 3D cell cultures provides the ability to generate in vivo-like data with the speed and quality of in vitro screenings.
3D HCS represents a step between classical in vitro 2D monolayer HCS and in vivo studies in animals, 3D HCS provides a unique opportunity to test large collections of molecules in a relevant quasi-physiological environment.

A wide range of microtissues

Fluofarma assays can be combined with spheroid microtissues obtained from various primary cell cultures or cell lines.

As cells from spheroid 3D microtissues are highly differentiated compared to the same cells in 2D cultures, they are the best predictive model prior to the evaluation of your drug in vivo.

Composite microtissues are also possible such as:

► Dual cell type spheroid microtissues

- Human cell line/fibroblast
- Human cell line/endothelial cells

► Tri cell type spheroids

- Human cell line/fibroblast/endothelial cells